301201 诚达药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.110-0.563-1.2724.0517.762
总资产报酬率 ROA (%)0.098-0.498-1.1493.8097.087
投入资产回报率 ROIC (%)0.106-0.538-1.2294.0047.529

边际利润分析
销售毛利率 (%)30.88744.17142.82142.88648.009
营业利润率 (%)1.276-1.927-7.37526.01930.196
息税前利润/营业总收入 (%)2.274-3.023-9.37223.29927.876
净利润/营业总收入 (%)0.897-2.943-8.29721.98925.878

收益指标分析
经营活动净收益/利润总额(%)-22.540-37.324220.51260.24871.297
价值变动净收益/利润总额(%)242.151-114.545-119.15640.11933.021
营业外收支净额/利润总额(%)-52.68040.9629.614-3.404-3.445

偿债能力分析
流动比率 (X)6.5276.4266.8449.57816.876
速动比率 (X)5.7075.6956.1908.81715.305
资产负债率 (%)10.69110.75911.9347.1854.557
带息债务/全部投入资本 (%)2.2173.6134.6081.7320.077
股东权益/带息债务 (%)4,386.0602,661.0272,066.1775,660.638129,661.467
股东权益/负债合计 (%)834.297828.393737.0351,290.8642,092.776
利息保障倍数 (X)1.581-12.5517.730-12.503-21.210

营运能力分析
应收账款周转天数 (天)79.39789.655118.494100.94086.132
存货周转天数 (天)160.225225.090251.118218.244219.281